公开(公告)号：US20210121422A1

公开(公告)日：2021-04-29

申请号：US16969521

申请日：2019-02-13

Applicant: LIGAND PHARMACEUTICALS INCORPORATED ,  METAVANT SCIENCES GMBH

Inventor： Lin Zhi ,  Ian Henderson ,  Joseph Kaloko ,  Martin Osterhout

IPC: A61K31/185 ,  C07C309/24 ,  A61K31/155 ,  A61K31/427 ,  A61K31/4439 ,  A61K38/28 ,  A61K38/31 ,  A61K31/7032 ,  A61K31/702 ,  A61K31/64 ,  A61K31/366 ,  A61K31/455 ,  A61K45/06 ,  C07C315/04 ,  C07C201/12 ,  C07C209/36 ,  C07C67/343 ,  C07C67/00 ,  C07C231/02 ,  C07C231/12 ,  C07C315/06

Abstract: Provided herein are solid state forms of compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions and methods of treating, preventing, ameliorating, delaying the time to onset or reducing the risk for the development or progression of at least one condition, disease, or disorder for which one or more glucagon receptor antagonist is indicated, including Type I and II diabetes, insulin resistance, hyperglycemia, ketoacidosis, or ketosis.

公开(公告)号：US10988441B2

公开(公告)日：2021-04-27

申请号：US16689252

申请日：2019-11-20

Applicant: Valo Early Discovery, Inc.

Inventor： Kenneth W. Bair ,  Nicholas Barczak ,  Bingsong Han ,  David R. Lancia, Jr. ,  Cuixian Liu ,  Matthew W. Martin ,  Pui Yee Ng ,  Aleksandra Rudnitskaya ,  Jennifer R. Thomason ,  Mary-Margaret Zablocki ,  Xiaozhang Zheng

IPC: C07C259/06 ,  A61K31/185 ,  C07D221/20 ,  A61K31/438 ,  A61K31/277 ,  C07D209/44 ,  A61K31/4035 ,  C07D295/155 ,  A61K31/451 ,  C07D471/10 ,  A61K31/435 ,  C07D487/10 ,  A61K31/407 ,  C07D495/10 ,  A61K31/397 ,  C07D235/14 ,  A61K31/4184 ,  C07D233/68 ,  A61K31/417 ,  C07D213/56 ,  A61K31/44 ,  C07D241/08 ,  A61K31/495 ,  C07D417/04 ,  A61K31/4439 ,  A61K31/5377 ,  C07D471/04 ,  C07D401/14 ,  C07D213/75 ,  C07D213/81 ,  C07D215/12 ,  C07D317/68 ,  C07D231/14 ,  C07D231/18 ,  C07D233/36 ,  C07D233/38 ,  C07D333/70 ,  C07D401/04 ,  C07D401/12 ,  C07D235/30 ,  C07D239/20 ,  C07D239/22 ,  C07D405/12 ,  C07D409/04 ,  C07D409/12 ,  C07D241/12 ,  C07D417/12 ,  C07D249/18 ,  C07D257/04 ,  C07D261/18 ,  C07D487/04 ,  C07D487/08 ,  C07D491/10 ,  C07D207/10 ,  C07D493/08 ,  C07D207/267 ,  C07D498/04 ,  C07D209/08 ,  C07D277/56 ,  C07D209/42 ,  C07D209/46 ,  C07D513/10 ,  C07D211/16 ,  C07D211/58 ,  C07D295/192 ,  C07D213/65 ,  C07D307/68

Abstract: The present invention relates to inhibitors of histone deacetylases, in particular HDAC8, that are useful for the treatment of cancer and other diseases and disorders, as well as the synthesis and applications of said inhibitors.

公开(公告)号：US10945979B1

公开(公告)日：2021-03-16

申请号：US15841003

申请日：2017-12-13

Applicant: Carl Louis Schroeder

Inventor： Carl Louis Schroeder

IPC: A61K31/198 ,  A61K31/185 ,  A61K9/48 ,  A61K31/522 ,  A23L33/175 ,  A23L2/60 ,  C12G3/04 ,  A61K9/00

Abstract: Amino acid compositions for promoting vascular endothelial health include arginine, citrulline, and taurine. Compositions may be combined with additional ingredients to form beverages, concentrates, and non-liquid food compositions. Methods of making concentrate compositions, beverage compositions, and non-liquid food compositions are provided. Methods of administering compositions to improve endothelial health, treat endothelial dysfunction, treat sexual dysfunction, treat altitude sickness, treat decompression sickness, treat jet lag, and treat fatigue include administering compositions including arginine, citrulline, and taurine.

公开(公告)号：US20210069134A1

公开(公告)日：2021-03-11

申请号：US16880796

申请日：2020-05-21

Applicant: The Research Foundation For SUNY

Inventor： Lorenz Simon Neuwirth ,  Bright U. Emenike

IPC: A61K31/185 ,  A61P39/02

Abstract: Disclosed are the methods and compositions for treating, ameliorating, or preventing neurological symptoms or conditions associated with lead (Pb2+) poisoning, and, also for reversing the damage caused by prolonged or acute lead (Pb2+) exposure. Compositions comprised of taurine or derivatives thereof, and optionally an injectable formulation, are also disclosed.

公开(公告)号：US10925849B2

公开(公告)日：2021-02-23

申请号：US16088312

申请日：2017-03-15

Applicant: Queen Mary University of London

Inventor： Madusha Peiris ,  Ashley Blackshaw

IPC: A61K31/20 ,  A61K31/01 ,  A61K45/00 ,  A61K36/55 ,  A61P3/00 ,  A61K31/192 ,  A61K31/185

Abstract: The present invention provides compositions and pharmaceutical compositions of GPR84 agonists and GPR120 agonists for us in the treatment of obesity and overweight. The invention provides methods of treatment accordingly as well as a kit for use in the treatment of obesity and overweight.

公开(公告)号：US10918650B2

公开(公告)日：2021-02-16

申请号：US15612642

申请日：2017-06-02

Applicant: UNIVERSITY OF SOUTH FLORIDA ,  UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.

Inventor： Mildred Enid Acevedo-Duncan ,  Wishrawana Ratnayake ,  David A. Ostrov

IPC: A61K31/675 ,  A61K31/122 ,  G01N33/574 ,  A61K31/185 ,  C12Q1/6886 ,  A61K45/06 ,  A61K31/255 ,  A61K31/194

Abstract: The invention pertains to a method of treating melanoma by administering to a subject in need thereof, a composition comprising a therapeutically effective amount of an inhibitor of PKC-ζ and/or PKC-ι. Non-limiting examples of an inhibitor of PKC-ζ and/or PKC-ι include ICA-1 and ACPD. The invention also provides PKC-ζ and/or PKC-ι as biomarkers for identifying a melanoma in a subject as likely to be responsive or non-responsive to a therapy using an inhibitor of PKC-ζ and/or PKC-ι. Accordingly, a method of identifying a subject having a melanoma as being responsive or non-responsive to a melanoma therapy with an inhibitor of PKC-ζ and/or PKC-ι based on the levels and/or activity of PKC-ζ and/or PKC-ι mRNA or protein in the melanoma cells from the subject are also provided.

公开(公告)号：US10918612B2

公开(公告)日：2021-02-16

申请号：US14157986

申请日：2014-01-17

Applicant: Markus Zwickl

Inventor： Markus Zwickl

IPC: A61K31/00 ,  A61K45/00 ,  A61K31/185 ,  A61K31/216 ,  A61K31/4184 ,  A61K31/4422 ,  A61K31/549 ,  A61K31/5513 ,  A61K31/4035 ,  A61K45/06 ,  A61K31/4178 ,  A61K31/41 ,  A61K31/4245

Abstract: The invention relates to a pharmaceutical combination of 2-aminoethanesulfonic acid with a pharmaceutical agent such as an antihypertensive agent and the use of 2-aminoethanesulfonic acid in a method to lower the bilirubin level in the blood.

公开(公告)号：US20210030701A1

公开(公告)日：2021-02-04

申请号：US16903064

申请日：2020-06-16

Applicant: Icahn School of Medicine at Mount Sinai

Inventor： Adam S. MORGENTHAU

IPC: A61K31/185 ,  A61K45/06 ,  A61K9/00

Abstract: The present disclosure relates to methods for the treatment of sarcoidosis. In certain aspects and embodiments, the disclosure provides compositions containing 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof and/or the use of such compositions for the treatment of Sarcoidosis. In another aspect, the disclosure relates to compositions containing 1,3-propanedisulfonic acid or a pharmaceutically acceptable salt thereof plus a second active agent. In yet another aspect, the disclosure relates to kits containing agents useful for the treatment of sarcoidosis.

公开(公告)号：US10881630B2

公开(公告)日：2021-01-05

申请号：US16504702

申请日：2019-07-08

Applicant: Vireo Systems, Inc. ,  Board of Regents of the University of Nebraska

Inventor： Donald W. Miller ,  Jonathan L. Vennerstrom ,  Mark C. Faulkner

IPC: A61K31/198 ,  A23L33/10 ,  A23L33/175 ,  A61K31/195 ,  A61K31/661 ,  A23K20/105 ,  A23K20/142 ,  A23K50/10 ,  A23L2/52 ,  A61K31/185 ,  A23K20/10 ,  A61K9/00 ,  A23P10/40

Abstract: The present invention is directed to an oral supplement including creatine hydrochloride, which has an aqueous solubility that is at least 15 times greater than creatine monohydrate, where the oral supplement drives significant improvements in muscle development and recovery due to its enhanced bio-availability, while causing fewer negative side effects compared to previous forms of creatine.

公开(公告)号：US20200376091A1

公开(公告)日：2020-12-03

申请号：US16891178

申请日：2020-06-03

Applicant: Vital Proteins, LLC

Inventor： Kurt SEIDENSTICKER ,  Matt APORTA ,  Corey FRIESE ,  Angela SKUBAL

IPC: A61K38/39 ,  A61K31/198 ,  A61K31/185 ,  A61K31/375 ,  A61K31/51 ,  A61K31/525 ,  A61K31/455 ,  A61K31/675 ,  A61K31/519 ,  A61K33/06 ,  A61K33/30 ,  A61K33/04 ,  A61K33/00 ,  A61K9/14 ,  A23L33/175 ,  A23L33/155 ,  A23L33/00

Abstract: The present invention is directed to a method of replacing collagen broken down during physical activity using a novel dietary supplement. The supplement composition of the present invention comprises collagen, glutamine, taurine, and, optionally, the nine essential amino acids. The uptake of collagen is enhanced using this combination of components to levels substantially near the pre-workout levels.